Analyst Price Targets — ZLAB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 7, 2026 1:17 pm | — | UBS | $35.00 | $19.00 | TheFly | Zai Lab initiated with a Buy at UBS |
| June 30, 2025 5:43 pm | — | Leerink Partners | $75.00 | $34.97 | TheFly | Zai Lab price target raised to $75 from $73 at Leerink |
| March 7, 2025 11:46 am | — | Scotiabank | $55.00 | $36.42 | TheFly | Zai Lab initiated with an Outperform at Scotiabank |
| September 27, 2024 8:05 am | Jack Lin | Morgan Stanley | $50.00 | $23.63 | StreetInsider | Morgan Stanley on Zai Lab (ZLAB) Post BMY (BMY) Approval: 'We believe it should bode moderately positively for ZLAB shares' |
| April 21, 2022 11:15 am | — | Leerink Partners | $101.00 | $42.88 | Benzinga | SVB Leerink Maintains Outperform on Zai Lab, Lowers Price Target to $101 |
Latest News for ZLAB
Z.ai's shares rose after the company launched a new AI model that it claimed runs only on Chinese chips. It's the latest indication of China's efforts to ramp up homegrown computing capability.
ZLAB has grown from a Greater China licensing platform into a dual-engine biopharma. They have a growing proprietary global pipeline with KarXT and TIVDAK. And management expects product sales to stabilize during 2H2026. Zoci's SCLC and NEC activity looks promising, while their other partnered combo therapies could expand their indications across other treatments.
SHANGHAI & CAMBRIDGE, Mass. & AMSTERDAM--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & NASDAQ: ARGX), today announced positive topline results from the ALKIVIA Phase 3 study evaluating VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with autoimmune myositis. Study met its primary endpoint (p=0.0011) In the combined immune-mediated necrotizing myopathy (IMNM)…
Zai Lab NASDAQ: ZLAB said its second-quarter net product revenue rose 11% sequentially to $105.8 million as the company continued to invest in a pipeline it expects to support a transition into a global biopharmaceutical business.
Zai Lab Limited (ZLAB) Q2 2026 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ZLAB.
U.S. House Trading
No House trades found for ZLAB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.